{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T22:01:16Z","timestamp":1774648876136,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"am","delay-in-days":320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"University of North Carolina at Chapel Hill Center for AIDS Research (CFAR)"},{"name":"NIH funded program","award":["P30 AI50410"],"award-info":[{"award-number":["P30 AI50410"]}]},{"name":"NIH funded program","award":["R01 Al22319"],"award-info":[{"award-number":["R01 Al22319"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jpba.2017.10.030","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T18:30:35Z","timestamp":1509474635000},"page":"40-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Validation of an LC\u2013MS\/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots"],"prefix":"10.1016","volume":"149","author":[{"given":"Amanda P.","family":"Schauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mackenzie L.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela D.M.","family":"Kashuba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2017.10.030_bib0005","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0b013e3283522272","article-title":"Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention","volume":"26","author":"van der Straten","year":"2012","journal-title":"AIDS"},{"issue":"February (2)","key":"10.1016\/j.jpba.2017.10.030_bib0010","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jac\/dkq447","article-title":"Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection","volume":"66","author":"Anderson","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.jpba.2017.10.030_bib0015","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1371\/journal.pmed.0030454","article-title":"Criteria for drugs used in pre-Exposure prophylaxis trials against HIV infection","volume":"3","author":"Derdelinckx","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.jpba.2017.10.030_bib0020","unstructured":"Truvada [Package Insert] Gilead Sciences Foster City, CA : 2011."},{"key":"10.1016\/j.jpba.2017.10.030_bib0025","unstructured":"Epivir [Package Insert] GlaxoSmithKline Research Triangle Park, NC: 2017."},{"issue":"4","key":"10.1016\/j.jpba.2017.10.030_bib0030","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1310\/hct0904-238","article-title":"White coat compliance limits the reliability of therapeutic drug monitoring in HIV-1\u2014infected patients","volume":"9","author":"Podsadecki","year":"2008","journal-title":"HIV Clin. Trials"},{"issue":"February (2)","key":"10.1016\/j.jpba.2017.10.030_bib0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/aid.2012.0089","article-title":"Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure","volume":"29","author":"Castillo-Mancilla","year":"2013","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"October (11)","key":"10.1016\/j.jpba.2017.10.030_bib0040","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1128\/AAC.01017-16","article-title":"Emtrictabine-triphosphate in dried blood spots as a marker of recent dosing","volume":"60","author":"Castillo-Mancilla","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"November (9)","key":"10.1016\/j.jpba.2017.10.030_bib0045","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/infdis\/jiv239","article-title":"Strong correlation between concentrations of tenofovir (TFV) emtricitabine (FTC) in hair and TFV diphosphate and FTC triphosphate in dried blood spots in the iPrEx open label extension: implications for pre-exposure prophylaxis adherence monitoring","volume":"212","author":"Gandhi","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jpba.2017.10.030_bib0050","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy:the DOT-DBS study","author":"Anderson","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"April","key":"10.1016\/j.jpba.2017.10.030_bib0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpba.2016.01.038","article-title":"Application of an intracellular assay for determination of Tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using Dried Blood Spots","volume":"122","author":"Zheng","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.10.030_bib0060","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/mas.20280","article-title":"Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs","volume":"30","author":"Jansen","year":"2011","journal-title":"Mass Spectrom. Rev."},{"issue":"November (29)","key":"10.1016\/j.jpba.2017.10.030_bib0065","first-page":"3659","article-title":"On-line coupling of anion exchange and ion-pair chromatography for measurement of intracellular triphosphate metabolites of reverse transcriptase inhibitors","volume":"877","author":"Z","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2017.10.030_bib0070","unstructured":"Lesotho Country Operation Plan (COP\/ROP) 2017\u2013Pepfar, www.pepfar.gov\/documents\/organization\/272218."},{"key":"10.1016\/j.jpba.2017.10.030_bib0075","unstructured":"WHO. Mar ch 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach."},{"key":"10.1016\/j.jpba.2017.10.030_bib0080","unstructured":"Analytical Procedures and Methods Validation for Drugs and Biologics The Food and Drug Administration. 27 July 2015.80 FR 44357."},{"issue":"January (2)","key":"10.1016\/j.jpba.2017.10.030_bib0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jchromb.2005.11.009","article-title":"Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis","volume":"830","author":"Matuszewski","year":"2006","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708517321763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708517321763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:52:06Z","timestamp":1759999926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708517321763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":17,"alternative-id":["S0731708517321763"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2017.10.030","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of an LC\u2013MS\/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2017.10.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}